GleamWall
中文EN

BTAIQ BioXcel Therapeutics, Inc.

Pharmaceutical Preparations · OTC · SEC CIK 1720893 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY-14.5%
TTM net income YoY-39.1%
TTM EPS YoY78.3%
Revenue 3-yr CAGR-10.6%
Net income 3-yr CAGR—

Margins

Gross margin53.1%
Operating margin-6,054.7%
Net margin-9,549.9%
FCF margin-6,860.4%
EBITDA margin-6,024.4%

Returns

ROE—
ROA-259.6%
ROIC (approx.)—
Asset turnover0.03x

Leverage & solvency

Liabilities / assets500.9%
Debt / equity—
Current ratio0.21x
Interest coverage-2.61x

Cash quality & payout

Operating cash flow / net income0.72x
Accruals ratio-73.1%
Payout ratio—
Capex / revenue0.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$642,000$2.27M
Cost of revenue$164,000$2.14M
Gross profit$478,000$123,000
R&D expense$30.25M$30.43M
SG&A expense$20.49M$34.49M
Operating income-$50.46M-$67.25M
Interest expense$16.98M$15.13M
Income tax$0$0
Net income-$69.90M-$59.60M
EBITDA-$50.16M-$66.94M
EPS (basic)-5.73-23.51
EPS (diluted)-5.73-23.51
Weighted avg. shares (diluted)12.21M2.54M
Balance sheet
Cash & equivalents$28.41M$29.85M
Receivables$233,000$131,000
Inventory$722,000$679,000
Current assets$44.69M$37.39M
PP&E, net$175,000$475,000
Total assets$44.92M$38.34M
Current liabilities$53.93M$22.23M
Short-term debt$24.93M$0
Long-term debt$84.66M$102.51M
Total debt$109.59M$102.51M
Total liabilities$140.38M$131.44M
Shareholders' equity-$95.46M-$93.10M
Net debt$81.18M$72.65M
Shares outstanding22.33M3.10M
Cash flow statement
Operating cash flow-$57.62M-$72.03M
Capital expenditure$0$0
Free cash flow-$57.62M-$72.03M
Investing cash flow$0$0
Financing cash flow$56.52M$36.66M
Depreciation & amortization$300,000$309,000
Stock-based compensation$2.77M$6.16M

Free plan shows the latest 2 periods; Pro shows all 9 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.